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Inflammatory breast cancer (IBC) is a highly metastatic, aggressive, and fatal form of breast
cancer. Patients presenting with IBC are characterized by a high number of axillary lymph
node metastases. Recently, we found that IBC carcinoma tissues contain significantly
higher levels of human cytomegalovirus (HCMV) DNA compared to other breast cancer
tissues that may regulate cell signaling pathways. In fact, HCMV pathogenesis and clin-
ical outcome can be statistically associated with multiple HCMV genotypes within IBC.
Thus, in the present study, we established the incidence and types of HCMV genotypes
present in carcinoma tissues of infected non-IBC versus IBC patients. We also assessed
the correlation between detection of mixed genotypes of HCMV and disease progression.
Genotyping of HCMV in carcinoma tissues revealed that glycoprotein B (gB)-1 and gly-
coprotein N (gN)-1 were the most prevalent HCMV genotypes in both non-IBC and IBC
patients with no significant difference between patients groups. IBC carcinoma tissues,
however, showed statistically significant higher incidence of detection of the gN-3b geno-
type compared to non-IBC patients. The incidence of detection of mixed genotypes of gB
showed that gB-1+gB-3 was statistically significantly higher in IBC than non-IBC patients.
Similarly, the incidence of detection of mixed genotypes of gN showed that gN-1+gN-3b
and gN-3+gN-4b/c were statistically significant higher in the carcinoma tissues of IBC
than non-IBC. Mixed presence of different HCMV genotypes was found to be significantly
correlated with the number of metastatic lymph nodes in non-IBC but not in IBC patients.
In IBC, detection of mixed HCMV different genotypes significantly correlates with lym-
phovascular invasion and formation of dermal lymphatic emboli, which was not found in
non-IBC patients.
Keywords: human cytomegalovirus, glycoproteins, inflammatory breast neoplasms, UL55, UL73, lymphovascular
invasion, metastasis
INTRODUCTION
Breast cancer is considered the most common malignancy and a
leading cause of death in women worldwide (1). Many risk fac-
tors including age, sex, obesity, estrogen level, and family history
of breast cancer are contributors to increased breast cancer inci-
dence (2). Studies suggest that viral infection maybe a risk factor
in breast cancer (3, 4). For instance, a link between certain viral
infections and breast cancer incidence is suspected for Epstein–
Barr virus (EBV) (5), human papillomavirus (HPV) (6), mouse
mammary tumor virus (MMTV) (7), and human cytomegalovirus
(HCMV) (8), although causality remains unproven. HCMV has
been detected in newly diagnosed (9) and metastatic breast can-
cer patients (10). Furthermore, HCMV proteins and DNA have
been detected in breast ductal carcinoma in situ (DCIS) and
infiltrating ductal carcinoma tissues, possibly suggesting a causal
association of HCMV in breast carcinogenesis (8). The ability of
HCMV to infect a wide variety of cells constituting the tumor
microenvironment, such as monocytes/macrophages, fibroblasts,
and endothelial cells, implicates a variety and possible mechanisms
for HCMV in cancer pathogenesis (11–13).
During one’s lifetime, infection with several HCMV strains may
occur (14). The virulence among different HCMV strains may
be a crucial factor in the manifestation of HCMV-associated dis-
ease (15). It should be noted that genetic variation exists among
HCMV genes that are implicated in host cell penetration, tissue
tropism, or replication, which may influence the virulence of dif-
ferent HCMV strains (16). The severity of HCMV pathogenicity
differs depending on genetic variability within viral genes (17).
Among the most variable HCMV genes are the viral envelope gly-
coproteins such as UL55 that encodes glycoprotein B (gB) (18),
and UL73 that encodes glycoprotein N (gN) (19). The gB geno-
type includes five genotypes (gB-1–gB-5) (20), while gN shows
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four genotypes (gN-1, gN-2, gN-3, and gN-4). The gN-3 geno-
type includes two subgenotypes (a and b) and gN-4 includes three
subgenotypes (a, b, and c) (21).
Human cytomegalovirus gB is the major component of the
virus envelope; it plays an essential role in viral entry into the cell
by binding to membranous beta-1 integrin via its gB disintegrin-
like domain, which mediates virus entry to the host cell and cell
to cell virus transmission (22). Virus binding to the cell surface
induces the phosphorylation of β1 and β3 integrins’ intracellular
domains (23). The gN moiety is covalently linked through disul-
fide bonds with glycoprotein M to form gM/gN complex (24). It
is assumed that gN alone or the gM/gN complex is implicated
in virus entry and spread, and is essential for HCMV replication
(25). Recently, it was found that the glycosylation of gN protects
the virus from neutralizing antibodies (26).
Human cytomegalovirus cellular entry activates intracellu-
lar signaling pathways such as focal adhesion kinase (FAK)
(23), mitogen-activated protein kinase (MAPK) (27), and
phosphatidylinositol-3-OH kinase (PI3-K) (28) all of which are
known to play key roles in cancer progression (29–31). In addition,
they played the role of HCMV gB in cell adhesion and signal-
ing capabilities (22, 23). HCMV infection is involved in cancer
pathogens via modulation of apoptosis, cell migration, and angio-
genesis (32). In fact, mixed infections with different genotypes of
HCMV were detected in healthy (14) and immuno-suppressed
patients, including patients undergoing lung transplant (33) and
AIDS patients (34). In addition, mixed genotypes infection was
found to be associated with increased morbidity and mortality of
solid organ transplant patients (35, 36).
We are interested in the biology of inflammatory breast can-
cer (IBC), an aggressive and fatal form of breast cancer that
occurs at increased incidence among young women (37–41). Our
recent results found, for the first time, that their increased tumor-
associated monocytes/macrophages (TAM/M) and HCMV infec-
tion in the biology of IBC disease (42, 43). We found that cytokines
secreted by IBC TAM/M such as IL-10 and IL-8 may be associ-
ated with HCMV infection. We screened for HCMV infection in
IBC versus non-IBC patients. Serological diagnosis indicates that
HCMV antibody titer was higher in IBC versus non-IBC. Further-
more, nested PCR results revealed that HCMV-DNA was detected
in carcinoma tissues of IBC and not in adjacent non-carcinoma tis-
sues, which was statistically significant compared to the non-IBC
patient group. Moreover, we found that the expression and acti-
vation (phosphorylation) of NF-κB/p65 signaling molecules are
enhanced in HCMV-infected IBC cancer tissues compared to non-
IBC tumors. These data all suggest a possible pathogenic role of
HCMV in IBC at a greater level than in non-IBC carcinomas (43).
In the present study, we established the incidence of single and
mixed HCMV gB and gN genotypes DNA in carcinoma tissues of
non-IBC versus IBC patients. Furthermore, we assessed the corre-
lation between mixed genotypes and major pathological properties
associated with breast cancer disease progression.
MATERIALS AND METHODS
PATIENTS AND SAMPLES
For participation of patients in this study, Institutional Review
Board (IRB) approval was obtained from the ethics committee
of Ain-Shams University. Each patient before participation pro-
vided a signed consent form including approval for publication of
results. Patients visiting the breast clinic of Ain-Shams University
hospitals and diagnosed with breast cancer by clinical exami-
nation, mammography, ultrasound, and tru-cut biopsy (using a
needle for manual culture of the breast tissues) were recruited to
the present study (42). In addition to the previous criteria, breast
cancer patients presenting with swollen breast, edema, skin orange
peel (pead’orange), both skin and core biopsies showed infiltra-
tion of dermal lymphatics by carcinoma cells and the presence of
dermal tumor emboli, as we described previously (40) and were
diagnosed as IBC patients. By applying these criteria, a total of
147 patients (99 non-IBC and 48 IBC) with HCMV-DNA positive
carcinoma tissue samples (43) were recruited in the present study
during the period of January 2010–September 2013.
MULTIPLEX PCR ASSAY FOR HCMV GLYCOPROTEINS B AND N
GENOTYPES
We extracted DNA from fresh breast carcinoma tissues obtained
during modified radical mastectomy using GeneJET™ Genomic
DNA purification Kit (Thermo scientific, Waltham, MA, USA).
Experimental procedures were carried out as described in the kit
guidelines. The oligonucleotide primers used for nested and mul-
tiplex PCR were commercially synthesized (Invitrogen, Carlsbad,
CA,USA) and are listed in Table 1. Detection of HCMV-DNA from
breast carcinoma tissue samples was carried out using nested PCR
with two sets of primers specific for the fourth exon of the HCMV
Immediate Early (IE) gene as we described previously (43). Geno-
typing of HCMV gB and gN was performed by multiplex PCR
using a mixture of specific primers to each of gB and gN geno-
types. For detection of different gB genotypes, nested multiplex
PCR was performed with two external primers and five upstream
inner primers specific for each gB genotype (gB-1,gB-2,gB-3,gb-4,
and gB-5) and a single downstream primer as described elsewhere
(44). The first round of the nested multiplex PCR was carried
out in a 25µl total volume using 1µl of each external upstream
and downstream primers (10 pmol\ml), 3µl of DNA, containing
a maximum of 250 ng DNA from fresh breast carcinoma tissue,
12.5µl of EmeraldAmp® MAX PCR green master mix (Takara,
Dalian, China), and 7.5µl of free RNase water. The PCR thermal
profile started with an initial denaturation at 94°C for 5 min, fol-
lowed by 35 cycles at 94°C for 45 s, 60°C for 1 min, and 72°C for
45 s, followed by terminal extension at 72°C for 10 min. The sec-
ond round of PCR was performed using 5µl of the first reaction
as DNA template and an equimolar mixture of 10 pmol of each
inner primer in a 25µl total volume. Reaction was carried out
under conditions identical to those used in the first round, but the
annealing temperature was 58°C instead of 60°C. For detection of
gN genotypes, multiplex PCR was done with five specific upstream
primers for each gN genotypes (gN-1, gN-2, gN-3b, gN-4a, and
gN-4b/c) and single downstream primers as described elsewhere
(45). The reaction was carried out with an equimolar mixture of
10 pmol of the five upstream primers and the single downstream
primer in a 25µl total volume with a thermal profile including
an initial denaturation at 94°C for 5 min, followed by 35 cycles
of 94°C for 45 s, 60°C for 1 min, and 72°C for 45 s, followed by
terminal extension at 72°C for 10 min.
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Table 1 | Primers sequences, target gene, and expected amplicon length used in viral screening.
Gene Target Direction Sequence Product (bp)
UL55 Entire gene amplification F GGGAGCCGCACCGACCTT 2782
R GGTCACGCCGCCGCTCAG
Nested multiplex PCR F (external) TTTGGAGAAAACGCCGAC 751
R (external) GCGGCAATCGGTTTGTTGTA
F1 (inner) ATGACCGCCACTTTCTTATC 420
F2 (inner) TTCCGACTTTGGAAGACCCAAC 613
F3 (inner) TAGCTCCGGTGTGAACTCC′ 190
F4 (inner) ACCATTCGTTCCGAAGCCGAGGAGTCA 465
F5 (inner) TACCCTATCGCTGGAGAAC 139
R (inner) GTTGATCCACACACCAGGC
UL73 Entire gene amplification F TGGTGTGATGGAGTGGAAC 421
R TAGCCTTTGGTGGTGGTTGC
Multiplex PCR F1 TTCTGCTAGCGTATCAACTACC 283
F2 AGTGCAAAACACTGG TGCT 380
F-3b CACAACCACATTAACGAGT 214
F-4a CAACAATACGTCGACT GCTAGCACAC 325
F-4b/c GACAACTAGT ACAACTACGGTGACAA 244
R GACATTGCTGCTTCCAGAA
Source of the primers.
UL55 entire gene amplification primers are described by Meyer-Konig et al. (14).
UL55 nested multiplex PCR primers are described by Tarrago et al. (44).
UL73 entire gene amplification primers are described by Yan et al. (46).
UL73 multiplex PCR primers are described by Pignatelli et al. (45).
AMPLIFICATION OF gB AND gN ENTIRE GENES
For gB and gN sequencing, the entire gB gene (2782 bp) was ampli-
fied in a 50µl total volume containing 1µl of each upstream and
downstream primers (10 pmol\ml), 5µl of the DNA containing a
maximum 300 ng DNA from fresh breast carcinoma tissue, 25µl
of EmeraldAmp® MAX PCR green master mix, and 18µl of free
RNase water. The thermal profile included an initial denaturation
at 94°C for 5 min, followed by 35 cycles of 94°C for 45 s, 60°C
for 1 min, and 72°C for 2 min, followed by terminal extension at
72°C for 10 min as described by Meyer-Konig et al. (14). Similarly,
the entire gN gene (418 bp) was amplified, the thermal profile
included an initial denaturation at 94°C for 5 min, followed by 35
cycles of 94°C for 45 s, 53°C for 1 min, and 72°C for 1 min, fol-
lowed by terminal extension at 72°C for 10 min as described by
Yan et al. (46).
AGAROSE GEL ELECTROPHORESIS OF PCR PRODUCTS
Amplified PCR products were visualized on 2% agarose gels (Bio
Basic Inc., Canada), stained with ethidium bromide, and pho-
tographed by the GBOX-F3 gel documentation system Syngene
(Syngene, MD, USA). All PCR reactions were conducted using
sterilized tubes and tips in a biosafety hood that was not previously
exposed to any virology work.
DNA SEQUENCING OF PCR PRODUCTS
To assure the results of HCMV genotyping, the entire gB and gN
genes were sequenced. We purified 18 randomly selected agarose
gel PCR products (9 non-IBC and 9 IBC) using GeneJET™ Gel
Extraction Kit (Thermo scientific, Waltham, MA, USA). Purified
PCR products were commercially sequenced at GATC-Biotech
(Konstanz, Germany). Single-pass sequencing was performed on
each sample using the same upstream and downstream primers
used in the amplification of the entire gB and gN genes. Con-
firmation of viral DNA sequences and multiple alignments were
performed using NCBI Blast search analysis.
STATISTICAL ANALYSIS
Data were expressed as mean± SD. Statistical differences or com-
parison between two groups was assessed by Student’s t -test
and Fisher’s exact test. Correlation was assessed by Pearson’s
correlation coefficient using SPSS 18.0 software (43).
RESULTS
CLINICAL AND PATHOLOGICAL CHARACTERIZATION OF NON-IBC
VERSUS IBC PATIENTS
Clinical and pathological characterization of patients who par-
ticipated in the present study is described in Table 2. The status
of lymph node metastasis showed that IBC patients had a sig-
nificantly (p= 0.001) higher number of metastatic lymph nodes
compared to non-IBC patients consistent with the typically higher
stage at presentation. In addition, the status of lymphovascular
invasion and presence of dermal lymphatic emboli in IBC patients
was significantly higher (p= 0.001) than in non-IBC patients,
again consistent with determination of IBC.
gB-1 AND gN-1 ARE THE MOST PREVALENT HCMV GENOTYPES FOUND
IN BREAST CANCER PATIENTS
Application of multiplex PCR for genotyping of HCMV/gB and
gN in breast carcinoma tissue samples is shown in Figures 1A,B.
Statistical analysis revealed that gB was detected in 95.9% of all
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Table 2 | Clinical and pathological characterization of non-IBC versus
IBC patients.
Characteristic Non-IBC
(N =99)
IBC
(N =48)
pValue
Age (years)
Range 27–78 29–72 0.152a
Mean±SD 52.35±11 49.52±11.59
Tumor size (cm)
Mean±SD 4.6±3.5 5.73±2.71 0.001*a
≤4 63 (63.6%) 17 (35.4%)
>4 36 (36.4%) 31 (64.6%)
Pathology
Invasive lobular carcinoma 7 (7.1%) 5 (10.4%) 0.345b
Invasive ductal carcinoma 92 (92.9%) 43 (89.6%)
Tumor grade
G1 4 (4.4%) 0 (0%) 0.202b
G2 78 (78.8%) 36 (75%)
G3 17 (17.2%) 11 (22.9%)
G4 0 (0%) 1 (2.1%)
Axillary lymph node metastasis
≤4 68 (68.7%) 15 (31.2%) 0.001*b
>4 31 (31.3%) 33 (68.8%)
Lymphovascular invasion
Negative 76 (76.8%) 16 (33.3%) 0.001*b
Positive 20 (20.2%) 32 (66.7%)
NA 3 (3%) 0 (0%)
ER
Negative 42 (42.4%) 23 (47.9%) 0.083b
Positive 47 (47.5%) 15 (31.3%)
NA 10 (10.1%) 10 (20.8%)
PR
Negative 46 (46.5%) 23 (47.9%) 0.138b
Positive 43 (43.4%) 15 (31.3%)
NA 10 (10.1%) 10 (20.8%)
Her-2
Negative 51 (51.5%) 24 (50%) 0.171b
Positive 38 (38.4%) 14 (29.2%)
NA 10 (10.1%) 10 (20.8%)
Data are reported as means±SD.
aStudent’s t-test.
bFisher’s exact test.
*Significant p value (p< 0.05).
NA=not available.
carcinoma tissue samples. In non-IBC breast carcinoma tissues,
gB-1 was the most prominent genotype representing 60.6% of all
infected carcinoma tissues, while gB-2, gB-3, gB-4, and gB-5 rep-
resents 15.2, 15.2, 12.1, and 9.1%, respectively. Similarly, in IBC
carcinoma tissues, gB-1 was the most prominent genotype, repre-
senting 58.3% of all positive carcinoma tissues, while gB-2, gB-3,
gB-4, and gB-5 represent 18.8, 25, 14.6, and 10.4%, respectively
(Figure 1C).
Glycoprotein N genotyping revealed that gN was detected in
97.45% of all carcinoma tissue samples. In non-IBC carcinoma
tissues, gN-1 was the most dominant genotype, representing
78.8% of all infected carcinoma tissues. gN-2, gN-3b, and gN-4b/c
represent 8.1, 7.1, and 12.1%, respectively. Similarly, in IBC carci-
noma tissues, gN-1 was the most prevalent genotype, representing
72.9% of all positive carcinoma tissues. The incidence of gN-2,
gN-3b, and gN-4b/c represent 14.6, 20.8, and 22.9%, respectively.
The incidence of gN-3b was significantly higher (p= 0.049) in IBC
carcinoma tissues compared to non-IBC tissues (Figure 1D).
PREVALENCE OF MIXED HCMV GENOTYPES IS PREDOMINANT AMONG
IBC CARCINOMA TISSUES COMPARED TO NON-IBC TISSUES
We compared the incidence of detection of HCMV gB and gN
genotypes DNA in non-IBC and IBC carcinoma tissues. Our
results showed that mixed incidence of gB and gN genotypes
was significantly higher (p= 0.048 and 0.002, respectively) in IBC
carcinoma tissues compared to non-IBC tissues (Figure 2).
Detection of mixed genotypes of HCMV in non-IBC and IBC
carcinoma tissues was assessed by multiplex PCR (Figures 3A,B).
Statistical analysis revealed that in non-IBC carcinoma tissues,
mixed infection with gB-1+ gB-4, gB-1+ gB-2, gB-1+ gB-3, and
gB-2+ gB-3 represents 8.1, 6.1, 4, and 1%, respectively. In IBC car-
cinoma tissues, we found that mixed infection with gB-1+ gB-3,
gB-1+ gB-2, gB-1+ gB-4, gB-2+ gB-3, and gB-2+ gB-4 repre-
sents 14.6, 6.3, 6.3, 2.1, and 2.1%, respectively (Figure 3C). Mixed
gB-2+ gB-4 genotypes could not be detected in non-IBC car-
cinoma tissues. Detection of mixed gB-1+ gB-3 genotypes was
significantly higher (p= 0.029) in IBC carcinoma tissue than
non-IBC tissues. Distribution of the detected mixed gN geno-
types revealed that in non-IBC carcinoma tissues, gN-1+ gN-4b/c,
gN-1+ gN-2, and gN-1+ gN-3b represent 4, 2, and 3%, respec-
tively. In IBC carcinoma tissues, gN-1+ gN-3b, gN-1+ gN-2, gN-
1+ gN-4b/c, gN-2+ gN-4b/c, and gN-3b+ gN-4b/c represent
12.5, 8.3, 4.2, 2.1, and 6.3%, respectively (Figure 3D). Detection of
mixed gN-1+ gN-3b genotypes and gN-3b+ gN-4b/c genotypes
was significantly higher (p= 0.034 and 0.033, respectively) in IBC
patient tissues than non-IBC tissues.
To validate these results, we conducted DNA sequence analysis
of whole genomes of gB and gN, and the entire gene sequences of
different gB and gN genotypes compared to those represented in
GenBank. The accession numbers KJ778194, KJ778196, KJ778198,
KJ778200, and KJ778202 represent the entire gB genotype (g1, g2,
g3, g4, and g5, respectively) sequences obtained from non-IBC
carcinoma tissues. The accession numbers KJ778193, KJ778195,
KJ778197, KJ778199, and KJ778201 represent the entire gB geno-
types sequence (gB-1, gB-2, gB-3, gB-4, and gB-5) sequences
obtained from IBC carcinoma tissues. The sequence of gN had
the accession numbers KF875977, KF875979, KF875981, and
KF875983, and represents the entire gN genotype (gN-1, gN-2,
gN-3b, and gN-1–4b/c) sequences obtained from non-IBC
carcinoma tissues. Accession numbers KF875976, KF875978,
KF875980, and KF875982 represent the entire gN genotypes
(gN1, gN-2, gN-3b, and gN-4b/c) sequences obtained from IBC
carcinoma tissues, respectively.
DETECTION OF MIXED HCMV DIFFERENT GENOTYPES SIGNIFICANTLY
CORRELATES WITH THE NUMBER OF METASTATIC LYMPH NODES IN
NON-IBC
To investigate whether detection of mixed HCMV genotypes is
associated with the metastatic behavior of breast carcinoma cells,
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FIGURE 1 | Distribution frequencies of HCMV genotypes in non-IBC
and IBC carcinoma tissues are shown. (A) Agarose gel electrophoresis
for nested multiplex PCR showed single detection of different HCMV gB
genotypes. Lane C− represents negative control; lanes 1 and 2 represent
gB-1 (420 bp) in non-IBC and IBC, respectively. Lanes 3 and 4 represent
gB-2 (613 bp) in non-IBC and IBC, respectively. Lanes 5 and 6 represent
gB-3 (190 bp) in non-IBC and IBC, respectively. Lanes 7 and 8 represent
gB-4 (465 bp) in non-IBC and IBC, respectively, and lanes 9 and 10
represent gB-5 (139 bp) in non-IBC and IBC, respectively. (B) Agarose gel
electrophoresis for multiplex PCR showed single detection of different
HCMV gN genotypes. Lane C− represents negative control; lanes 1 and 2
represent gN-1 (283 bp) in non-IBC and IBC, respectively. Lanes 3 and 4
represent gN-2 (380 bp) in non-IBC and IBC, respectively. Lanes 5 and 6
represent gN-3b (214 bp), in non-IBC and IBC, respectively, and lanes 7
and 8 represent gN-4b/c (244 bp) in non-IBC and IBC, respectively. (C) Bars
represent distribution frequencies of single infection with different HCMV
gB genotypes in non-IBC versus IBC carcinoma tissues. (D) Bars
represent distribution frequencies of single infection with different HCMV
gN genotypes non-IBC versus IBC carcinoma tissues. *Indicates a
significant p value as determined by Fisher’s exact test.
FIGURE 2 | Incidence of detection of mixed HCMV genotypes in
non-IBC and IBC carcinoma tissues is shown. Bars represent the
incidence of mixed presence of different HCMV gB and gN genotypes in
non-IBC and IBC carcinoma tissues as detected by multiplex PCR IBC
carcinoma tissues characterized by high incidence of mixed HCMV
genotypes compared to non-IBC carcinoma tissues.*Indicates a significant
p value as determined by Fisher’s exact test.
we assessed the distribution of the number of metastatic lymph
nodes among non-IBC and IBC patients with different gB and gN
genotypes. The number of metastatic lymph nodes in gB-1, gB-2,
gB-3, and gB-5 was significantly higher (p= 0.001, 0.009, 0.031,
and 0.001, respectively) in IBC than non-IBC patients (Figure 4A).
In addition, the number of metastatic lymph nodes in gN-1, gN-
3b, and gN-4b/c was significantly (p= 0.001, 0.006, and 0.019)
higher in IBC than non-IBC patients (Figure 4B). Interestingly,
detection of mixed HCMV different gB genotypes (Figure 5A)
and gN genotypes (Figure 5B) was statistically correlated with the
number of metastatic lymph nodes in non-IBC (p= 0.001 and
0.001, respectively) with a correlation coefficient of r = 0.550 and
0.437, respectively, and not in IBC.
DETECTION OF MIXED HCMV DIFFERENT GENOTYPES SIGNIFICANTLY
CORRELATES WITH LYMPHOVASCULAR INVASION AND FORMATION OF
DERMAL LYMPHATIC EMBOLI IN IBC
The status of lymphovascular invasion and formation of der-
mal lymphatic emboli (Figure 6) among carcinoma tissues con-
taining different gB and gN genotypes is described in Table 3.
Patients showing gB-1, gB-2, gB-3, and gB-5 were significantly
(p= 0.001, 0.016, 0.002, and 0.032, respectively) higher in IBC
than non-IBC patients. gN-1, gN-3b, and gN-4b/c were signif-
icantly (p= 0.001, 0.036, and 0.008, respectively) higher in IBC
than non-IBC patients. Detection of mixed HCMV different gB or
gN genotypes was found to be significantly correlated (p= 0.037 or
0.021, respectively) with lymphovascular invasion status in IBC. In
addition, detection of mixed HCMV different gB or gN genotypes
was statistically correlated with formation of dermal lymphatic
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FIGURE 3 | Incidence of detection of mixed HCMV different gB and gN
genotypes in non-IBC and IBC carcinoma tissues is shown.
(A) Agarose gel electrophoresis for nested multiplex PCR showed mixed
presence of different HCMV gB genotypes. Lane C− represents negative
control; lanes 1 and 2 represent gB-1+gB-2 (420 bp+613 bp) in non-IBC
and IBC, respectively. Lanes 3 and 4 represent gB-1+gB-3
(420 bp+ 190 bp) non-IBC and IBC, respectively. Lanes 5 and 6 represent
gB-1+gB-4 (420 bp+465 bp) in non-IBC and IBC, respectively. Lanes 7
and 8 represent gB-2+gB-3 (613 bp+190 bp) in non-IBC and IBC,
respectively. Lanes 9 and 10 represent gB-2+ gB-4 (613 bp+465 bp) in
non-IBC and IBC, respectively. (B) Agarose gel electrophoresis for
multiplex PCR showed mixed infection with different HCMV gN
genotypes. Lane C− represents negative control, lanes 1 and 2 represent
gN-1+gN-2 (283 bp+380 bp) in non-IBC and IBC, respectively, lanes 3
and 4 represent gN-1+gN-3b (283 bp+214 bp) in non-IBC and IBC,
respectively, lanes 5 and 6 represent gN-1+gN-4b/c (283 bp+244 bp) in
non-IBC and IBC, respectively, lanes 7 and 8 represent gN-2+gN-4b/c
(380 bp+244 bp) in non-IBC and IBC, respectively, and lanes 9 and 10
represent gN-3b+gN-4b/c (214 bp+244 bp) in non-IBC and IBC,
respectively. (C) Bars represent the incidence of mixed infection with
different HCMV gB genotypes in non-IBC and IBC carcinoma tissues as
detected by multiplex PCR. (D) Bars represent the incidence of mixed
infection with different HCMV gN genotypes. Non-IBC bar represents the
percentage of mixed gN genotypes infections in non-IBC and IBC
carcinoma tissues as detected by multiplex PCR. *Indicates a significant p
value as determined by Fisher’s exact test.
FIGURE 4 | Number of positive metastatic lymph nodes among
HCMV positive non-IBC and IBC patients by HCMV gB or gN
genotypes is shown. (A) Dots represent the numbers of metastatic
lymph nodes in non-IBC and IBC patients containing different HCMV
gB genotypes. (B) Dots represent the numbers of metastatic lymph
nodes in non-IBC and IBC patients containing different HCMV gN
genotypes. *Indicates a significant p value as determined by Student’s
T -test.
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FIGURE 5 | Association between lymph node metastasis and
mixed presence of HCMV genotypes in IBC and non-IBC patients
is shown. (A) Dots represent the numbers of metastatic lymph
nodes in non-IBC and IBC patients containing mixed HCMV gB
genotypes. (B) Dots represent the numbers of metastatic lymph
nodes in non-IBC and IBC patients with mixed HCMV gN genotypes.
Results showed that detection of mixed HCMV different gB or gN
genotypes statistically correlates with lymph node metastasis in
non-IBC. *Indicates a significant p value as determined by Pearson’s
correlation coefficient.
FIGURE 6 | Microscopic images of H and E stained paraffin
embedded tissue sections in breast carcinoma tissues are shown.
(A) Representative of paraffin embedded tissue section of non-IBC
carcinoma tissues showing invasion of carcinoma cells to lymphatic
vessels. (B) Representative of paraffin-embedded tissue section of IBC
carcinoma tissues showing tumor emboli formation due to carcinoma
cells invasion into lymphatic vessels (magnification: left panel, 10× and
right panel, 40×).
emboli in IBC (p= 0.01 or 0.004, respectively) and correlation
coefficient r = 0.368 and 0.408, respectively.
DISCUSSION
There is emerging evidence to suspect that viruses may play a
role in the development or progression of certain human can-
cers, possibly including breast cancer (47). Using nested PCR,
our previous results revealed that HCMV-DNA was detected in
carcinoma tissues of IBC and not in adjacent non-carcinoma
tissues, with results that are statistically significant compared to
non-IBC patients’ group. Interestingly, sequence analysis of the
detected HCMV-DNA fragments revealed that HCMV-infected
IBC carcinoma tissues contain different HCMV-strains when com-
pared to infected non-IBC tissues. Polymorphism among HCMV
strains may provide important clinical information on the involve-
ment of HCMV in IBC disease etiology (43). In fact, studies
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Table 3 | Incidence of lymphovascular invasion status among different gB and gN genotypes in non-IBC versus IBC patients.
HCMV glycoproteins Non-IBC lymphovascular
invasion status
IBC lymphovascular
tumor emboli
pValue
Positive Negative Positive Negative
gB GENOTYPES
gB-1 28.3% (n = 17) 71.7% (n = 43) 75% (n = 21) 25% (n = 7) 0.001*
gB-2 25% (n = 4) 75% (n = 12) 77.8% (n = 7) 22.2% (n = 2) 0.016*
gB-3 6.7% (n = 1) 93.3% (n = 14) 66.7% (n = 8) 33.3% (n = 4) 0.002*
gB-4 36.4% (n = 4) 63.6% (n = 7) 85.7% (n = 6) 14.3% (n = 1) 0.057
gB-5 12.5% (n = 1) 87.5% (n = 7) 80% (n = 4) 20% (n = 1) 0.032*
gN GENOTYPES
gN-1 21.8% (n = 17) 78.2% (n = 61) 74.3% (n = 26) 25.7% (n = 9) 0.001*
gN-2 37.5% (n = 1) 62.5% (n = 7) 57.1% (n = 4) 42.9% (n = 3) 0.100
gN-3b 14.3% (n = 1) 85.7% (n = 6) 70% (n = 7) 30% (n = 3) 0.006*
gN-4b/c 8.3% (n = 1) 91.7% (n = 11) 63.6% (n = 7) 36.4% (n = 4) 0.008*
*Significant p value (p< 0.05).
showed that HCMV is characterized by genetic variability among
its strains, which plays an important role in immune-pathogenesis
and stimulation of disease progression. In addition, the ability
of HCMV to infect different organs and cell types was found to
be related to gene sequence variation among strains (14, 48, 49).
Enhancement of CMV disease pathogenesis due to mixed strain
infection may result in expression and secretion of cytokines,
chemokines, and growth factors due to replication of different
virus strains (50). Indeed, cytokines, chemokines, and growth
factors secreted by breast carcinoma cells and tumor-associated
immune cells such as monocytes/macrophages play an essential
role in breast cancer progression (51), and may provide therapeutic
target molecules (42, 52).
The genomes of different HCMV strains are 95% homolo-
gous, but specific regions contain higher rates of mutation (53).
The most widely characterized polymorphic gene is UL55, which
encodes the viral gB genes, which is essential for virus penetration
and cell fusion (54), and represents the major target for neutral-
izing antibodies (55). The UL73 gene, which encodes viral gN
implicated in virus attachment to the host cell and spread from
cell to cell, is another highly polymorphic gene (56).
In the present study, we analyzed the incidence of gB and gN
genotypes in carcinoma tissues of breast cancer patients and its
association with breast cancer disease progression. Multiplex PCR
revealed that gB-1 is the most prevalent genotype in both non-
IBC and IBC carcinoma tissues with no significant difference
between both patient groups. The present result is in agreement
with previous studies, which reported that gB-1 had the highest
incidence in renal transplant recipient HCMV-infected patients in
Kuwait (57) and among children who live at the Phayathai Babies’
Home in Non-thaburi, Thailand (58). The predominance of the
gB-1 genotype in HCMV-infected patients was also recorded in
immunocompromised patients undergoing organ transplants (15)
and congenitally infected neonates (59, 60) in a Chinese popula-
tion. The gB-1 genotype was found to be the dominant HCMV
genotype detected in pregnant women, newborns, and infants.
The previous results increase the possibility that gB-1 might be
transmitted by breast feeding (58, 61, 62), and is more frequent in
women of different populations.
Similarly, we found that gN-1 is the most prominent genotype
in both non-IBC and IBC carcinoma tissues with no significant
difference between both patient groups. HCMV gN-1 was the
most incident genotype in monocytes isolated from healthy blood
donors (21). In this regard, HCMV gN-1 congenital infections are
associated with favorable chronic outcome (19). In the present
study, we found that IBC carcinoma tissues showed a statistically
significantly higher incidence of the gN-3b genotype compared to
non-IBC tissues.
Detection of mixed HCMV genotypes gB and gN was found
in urine and peripheral blood of healthy women (63) and in
vaginal specimens of women with sexually transmitted diseases
(64). Immunocompromised individuals acquire mixed infection
of HCMV genotypes (15, 33). Infection with mixed HCMV geno-
types was found to enhance immunopathogenesis (18) and mor-
bidity (65) among infected patients. In the present study, we found
that detection of mixed HCMV gB and gN genotypes were more
prominent in carcinoma tissues of IBC versus non-IBC patients.
Distribution of mixed presence of different gB genotypes showed
that gB-1+ gB-3 was statistically significantly higher in IBC than
non-IBC carcinoma tissues. IBC carcinoma tissues are character-
ized by highly invasive and angiogenic properties (66). Studies
showed that gB-1 is the most frequent genotype among kidney
transplant patients and induces the progression of invasive disease
in solid organ transplants (67). Other studies showed that geno-
types gB-1 and gB-3 are more prevalent among hematopoietic
stem cell transplant (HSCT) patients and that gB-3 is associ-
ated with the development of pneumonitis (68). A recent study
showed that HSCT patients presenting with the gB-3 genotype
are characterized by higher disease morbidity and lower survival
rates compared to patients harboring genotypes gB-1, -2, and -
4 (69). The aggressive behavior of genotype gB-3 may be due to
specific biological mechanisms associated with host–virus inter-
actions (70). Our present results suggest that the presence of
HCMV-gB-3 aggressive genotype among IBC patients might affect
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IBC poor prognosis and disease morbidity. In the present study,
we found that detection of mixed HCMV gN genotypes in breast
carcinoma tissues showed that gN-1+ gN-3b and gN-3+ gN-4b/c
were statistically significantly higher in IBC than non-IBC carci-
noma tissues. In particular, previous studies suggested that HCMV
may have a “strain-specific pathogenic phenotype,” which may
be due to a link conferred by polymorphic gN genes and their
function together (18, 71, 72).
Prospective survival rates among breast cancer patients are
determined by the potential of carcinoma cells to invade lymph
nodes and the number of metastatic axillary lymph nodes involved
(73). A study conducted by Soderberg-Naucler showed that
HCMV genes and proteins are present in the carcinoma tissues
and the sentinel lymph nodes of metastatic breast cancer patients
(74). An interesting study in cervical cancer showed that patients
co-infected with both HCMV and HPV 16 had a higher num-
ber of metastatic lymph nodes compared to HCMV−/HPV+ (75).
Indeed, HCMV-infected cells secrete cytokines and growth fac-
tors (secretome) that promote cellular motility, angiogenesis, and
lymphangiogenesis (12, 76). Over expression of US28 encoded
by HCMV is strongly associated with glioblastoma multiforme
tumor invasion, possibly via activation of VEGF, phosphoryla-
tion of STAT3 (p-STAT3), and endothelial nitric oxide synthase
(e-NOS) (77).
In the present study, we found that the number of metastatic
lymph nodes in patients with breast carcinoma tissues contain-
ing HCMV gB-1, gB-2, gB-3, and gB-5 was significantly higher in
IBC than non-IBC patients. Similarly, the number of metastatic
lymph nodes in gN-1, gN-3b, and gN-4b/c was statistically sig-
nificantly higher in IBC patients. IBC patients were characterized
by a statistically significantly higher number of axillary metastatic
lymph nodes compared to non-IBC patients. The novel results we
found here, that mixed infections with different gB or gN geno-
types significantly correlates with number of metastatic lymph
nodes in non-IBC patients, possibly indicates that mixed infec-
tion with HCMV genotypes may augment invasion and motility
of breast carcinoma cells.
Lymphovascular invasion is an important step in breast cancer
metastasis, with formation of lymphovascular emboli in IBC (78).
IBC is an aggressive form of breast cancer, characterized by forma-
tion of lymphatic emboli within the lymphatic vessels (79). HCMV
infection in tumor cells increases their adhesion to endothelium by
activation of β1α5 integrin on the surface of infected tumor cells,
which promotes tumor cell transmigration through the endothe-
lial cell barrier. The HCMV US28 pathway contributes to FAK
activation and stimulation of cell invasion in HCMV-infected
tumor cells (80, 81). Similar to results of lymph node metas-
tasis, lymphovascular invasion in patients demonstrating breast
carcinoma tissues with gB-1, gB-2, gB-3, and gB-5 genotypes was
statistically significantly higher in IBC than non-IBC tissues. In the
breast carcinoma tissues with single gN genotype, we found that
lymph node metastasis in gN-1, gN-3b, and gN-4b/c genotypes
was statically significantly higher in IBC than non-IBC patients.
Detection of mixed HCMV different genotypes significantly cor-
relates with lymphovascular invasion and formation of dermal
lymphatic emboli in IBC but not in non-IBC patients.
In conclusion, our present results suggest a possibility of a high
incidence of mixed HCMV genotypes infection in IBC, which may
play a role in IBC disease progression. Further studies are necessary
to determine the clinical significance of our findings and potential
treatment of HCMV-infected breast cancer patients.
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